Liam Mulroy

Clinical sites

Thoracic, Hematologic and CNS tumours

Education

• MD (University of Western Ontario)
  
• FRCPC (University of Toronto)

Research interests

• Palliative radiation for lung cancer
• Stereotactic radiation 
  
  

Administrative roles

• Director of Undergraduate Medical Education

Awards and honours

• Faculty of Medicine Excellence in Clinical Practice award - 2023 
• Teacher of the year – 2021, 2017
• Highest rate of accruals to clinical trials – 2015 & 2016

Recent publications

• X. Melody Qu, Yujie Chen, Gregory S. Zaric, Suresh Senan, Robert A. Olson, Stephen Harrow, Ava John-Baptiste, Stewart Gaede, Liam A. Mulroy, Devin Schellenberg, Sashendra Senthi, Anand Swaminath, Neil Kopek, Mitchell Liu, Andrew Warner, George B. Rodrigues, David A. Palma and Alexander V. Louie.  Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial.
• Alexander V. Louie,  Patrick V. Granton,  Alysa Fairchild,  Andrea Bezjak,  Darin Gopaul,            Mulroy L,  Anthony Brade, Andrew Warner, Brock Debenham, David Bowes, Joda Kuk, Alexander Sun, Douglas Hoover, George B. Rodrigues, David A. Palma.  Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE) A Phase 3 Randomized Clinical Trial.
• Palma D, Olson R, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman G, Laba J, Qu M, Warner A and Senan S.  Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long Term Resulsts of the SABR-COMET Phase II Radomized Trial, Journal of Clinical Oncology, 2830 Vol 38, Issue 25.
• Olson R, Senan S, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman G, Warner A, Palma D.   Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial. Int J Radiat Oncol Biol Phys. 2019 Aug 27
• Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, Rodrigues GB, Lock M, Yaremko BP, Bauman GS, Ahmad B, Schellenberg D, Liu M, Gaede S, Laba J, Mulroy L, Senthi S, Louie AV, Swaminath A, Chalmers A, Warner A, Slotman BJ, de Gruijl TD, Allan A, Senan S.   Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019 Aug 19
• Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.   Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman GS, Warner A, Senan S. Lancet. 2019 May 18